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CRYSTALLIZATION AND STRUCTURE OF A
PLANT PEPTIDE DEFORMYLASE

In some embodiments, the crystalline form includes a coor

dinated metal ion selected from the group of consisting of Fe,
Zn, and Ni, and any combination thereof. In one aspect, the
metal ion is coordinated by amino acid residues Cys171,
His2l3, and His2l7 of SEQ ID N011.
In another embodiment, a crystalline form of a polypeptide

CROSS REFERENCE TO RELATED
APPLICATIONS

This application claims priority to US. Provisional Appli
cation Ser. No. 60/835,823 ?led Aug. 4, 2006, the disclosure
of Which is incorporated herein by reference.

including a structure de?ned by one or more structure coor

dinates of Arabidopsis Zhaliana peptide deformylase amino
acid residues Gly121, Glyl23, Leul24, Gln128, Glul69,

Gly170, Cys171, Leul72, His2l3, Glu214, His2l7, and

STATEMENTS REGARDING FEDERALLY
SPONSORED RESEARCH

Tyr178 according to Table 1, is provided. In general, struc
tures derived from these crystalline forms encompass struc
tures having coordinates that differ by a root mean square
deviation ofless than about 1.5 A, 0.75 A, or 0.35 A, or any
deviation in this range, When superimposed on the non-hy

The invention Was funded in part by Grant No. MCB
MCB-0240165 aWarded by the National Science Foundation
(NSF). The government may have certain rights in the inven
tion.

drogen atom positions of the corresponding atomic coordi
nates of Table 1. In some aspects, amino acid residues

Gly121, Gly123,Leu124,Gln128, Glul69, Gly170,Cys171,

TECHNICAL FIELD

This invention relates to the crystallization and structure of

Leul72, His2l3, Glu2l4, His2l7, and Tyr178 include the
20

plant peptide deformylase and methods of using the structure.
BACKGROUND

Peptide deformylase (DEF; EC 3.5.1.88) is a metallopep

25

N-formyl methionine, Which is the initiating amino acid resi
30

polypeptide as provided herein.
35

In one embodiment, a computer system including a data
base containing information on the three dimensional struc
ture of a crystalline form of an Arabidopsis Zhaliana peptide
deformylase polypeptide and a user interface to vieW the

40

tem includes information related to diffraction data obtained

development of broad-spectrum antibiotics, Which Would
have little or no mammalian toxicity. In 2000 the existence of

information, is provided. In some aspects, the computer sys

DEF in the chloroplasts of higher plants Was reported, and it
Was also discovered that actinonin, a potent inhibitor of DEF,

from a crystalline form comprising SEQ ID N011. In other
aspects, the computer system of includes information related
to an electron density map of a crystal comprising SEQ ID

Was phytotoxic to all plant species. The lethality of actinonin
to a Wide range of plants, including many agriculturally sig
ni?cant Weed species, suggests that DEF is an essential and

N011.

highly conserved enzyme in plants, and inhibitors targeting
this enzyme could potentially serve as a neW class of broad
spectrum herbicides as Well as selectable markers.

45

50

With high speci?city toWards plant DEF.
SUMMARY

Provided herein are crystalline forms of a peptide deformy
lase, and atomic coordinates derived therefrom, useful for

55

coordinates for the amino acids including a root mean square
60

aspects, the crystalline form includes a structure character
of dimensions a, b, and c. In some aspects, a is about 40 A to

aspects, the polypeptide is a peptide deformylase isolated
from Arabidopsis Zhaliana.

includes information related to the structure coordinates for
one or more amino acid residues Gly121, Glyl23, Leul24,

His2l7, and Tyr178 according to Table 1, or similar structure

ized by tetragonal space group symmetry P412l2 and unit cell
about 60 A, b is about 40 A to about 60 A, and c is about 120
A to about 160 A. In other aspects, (XIBIYI9OO. In some

deviation of non-hydrogen atoms of less than about 1.5 A,
0.75 A, 0.35 A, or any percent in this range, When superim
posed on the non-hydrogen atom positions of the correspond
ing atomic coordinates of Table 1.
In other aspects, a computer system provided herein

Glnl28,Glul69,Gly170,Cys171,Leu172,His213,Glu214,

designing and identifying compounds that modulate the
activity of the peptide deformylase. Accordingly, in one
embodiment, a crystalline form of a polypeptide comprising
the amino acid residues of SEQ ID N011, is provided. In some

In another aspect, a computer system provided herein
includes information related to the structure coordinates of
Table 1 or homologous structure coordinates for the amino
acid residues of SEQ ID N011 that have a root mean square

Accordingly, plant peptide deformylase (DEF) polypep
tides provide an attractive target for crystallization and struc
tural studies Which can lead to the identi?cation and synthesis
of neW broad-spectrum herbicides and selectable markers

is provided.
In yet another embodiment, a machine-readable medium
embedded With information that corresponds to a three-di
mensional structural representation of a crystalline form of a

sively restricted to prokaryotes because protein translation in
eukaryotic organisms initiates With an unformylated
methionine residue. The restriction to prokaryotic organisms
and the essentiality of DEF have made this enzyme the
molecular target of many research efforts directed toWards the

provided herein also includes a ligand complexed With the
polypeptide. In some aspects, the ligand is a small molecule.
In another embodiment, a crystalline form of a polypeptide
that includes the amino acid residues of SEQ ID N011 and an
atomic structure characterized by the coordinates of Table 1,

tidase that catalyzes the removal of an N-formyl group from
due for prokaryotically translated proteins. DEF is an essen
tial enzyme and mutations, deletions, or insertions in the DEF
gene, or inhibition of enzymatic activity, are lethal to prokary
otic organisms. For decades DEF Was believed to be exclu

active site of the peptide deformylase. In some aspects, the
polypeptide includes an amino acid sequence having at least
75%, at least 85%, or at least 95%, or any percent in this
range, amino acid sequence identity to SEQ ID N011.
In other embodiments, a crystalline form of a polypeptide

deviation of non-hydrogen atoms of less than about 1.5 A,
0.75 A, 0.35 A, or any percent in this range, When superim
posed on the non-hydrogen atom positions of the correspond
ing atomic coordinates of Table 1.
In another embodiment, a method of identifying a candi

date compound that binds to the active site of Arabidopsis
65

Zhaliana peptide deformylase polypeptide, is provided. The
method includes comparing the atomic structure of the com
pound With a three-dimensional structure of a crystalline

US 7,445,923 B2
4

3
form of an Arabidopsis Zhaliana peptide deformylase
polypeptide and computationally identifying a candidate

In other aspects, the one or more molecular modeling tech

niques are selected from the group consisting of graphic

compound for an ability to bind to the Arabidopsis Zhaliana
peptide deformylase. In some aspects, the candidate com
pound binds to the active site of the Arabidopsis Zhaliana

molecular modeling and computational chemistry. In another
aspect, obtaining the atomic coordinates of the crystal

peptide deformylase. In other aspects, comparing the atomic

more amino acid residues Glyl 2 l, Glyl23, Leul 24, Glnl28,

includes detecting the interaction of the inhibitor to one or

structure of the compound With a three-dimensional structure

Glul69, Glyl70, Cys17l, Leu172, His2l3, Glu2l4, His2l7,

of a crystalline form of an Arabidopsis Zhaliana peptide

and Tyrl78 of SEQ ID NO:l.

deformylase polypeptide includes employing a computa

The details of one or more embodiments of the disclosure

tional means to perform a ?tting operation betWeen the com

lase.
In some embodiments, the candidate compound identi?ed

are set forth in the accompanying draWings and the descrip
tion beloW. Other features, objects, and advantages Will be
apparent from the description and draWings, and from the
claims.

by a computational method provided herein can be synthe
siZed and screened for the ability to bind a plant peptide

BRIEF DESCRIPTION OF DRAWINGS

pound and at least one binding site of the peptide deformy

deformylase in vitro or in vivo. In some aspects, the com
pound is an herbicide.
In another embodiment, a method of identifying a candi

FIG. 1A depicts a polyacrylamide gel shoWing that limited

date compound that binds to the active site of Arabidopsis

Zhaliana peptide deformylase polypeptide, is provided. The

20

trypsinolysis creates a core protein that retained activity and
remained soluble in the absence of high salt concentrations.
FIG. 1B depicts the amino acid sequence of the AtDEF

method includes comparing the atomic structure of the com
pound With a three-dimensional structural representation of a

peptide (SEQ ID NO: 1).

crystalline form provided herein and computationally identi

AtDEF2. The cylinders represent helices and the arroWs rep

FIG. 2A depicts a ribbon representation of crystallized
resent sheets.

fying a candidate compound for an ability to bind to the active

site of Arabidopsis Zhaliana peptide deformylase.

25

FIG. 2B depicts a slab vieW of the ribbon representation of

In yet another embodiment, a method of computationally
designing a candidate compound that binds to Arabidopsis

trypsinolyZed AtDEF2 highlighting the active-site-metal
binding ligands (l Cys and 2 His) from motifs II and III,

Zhaliana peptide deformylase polypeptide, is provided. The

respectively (EGCLS and QHEXXH) (SEQ ID NOS 15-16).

method includes comparing the atomic structure of chemical
entities, or fragments thereof, With a three-dimensional struc
tural representation of a crystalline form of a polypeptide

FIG. 3 depicts a graph of substrate speci?city comparison
30

of AtDEFl and AtDEF2.
FIG. 4 depicts a comparison of amino acid sequence con

provided herein; identifying chemical entities capable of

servation of the three motifs in AtDEFl and 2 and bacterial

associating With the three-dimensional structural representa

DEFs (SEQ ID NOS 2-5).

tion of a crystalline form of a polypeptide; and assembling the
chemical entities, or fragments thereof, into a single molecule
to provide the structure of the candidate compound. In some
aspects, the candidate compound binds to the active site of

35

Arabidopsis Zhaliana peptide deformylase.

Arabidopsis Zhaliana peptide deformylase.
In another embodiment, a method of identifying a region of

Arabidopsis Zhaliana peptide deformylase polypeptide that

40

contacts a compound, is provided. The method includes

obtaining X-ray diffraction data for a crystal of Arabidopsis

Zhaliana peptide deformylase; obtaining X-ray diffraction
data for a complex of a Arabidopsis Zhaliana peptide

deformylase and the compound; subtracting the X-ray dif
fraction data from the peptide deformylase With the X-ray

45

diffraction data obtained from the complex to obtain the dif

ference in the X-ray diffraction data; obtaining phases that
correspond to X-ray diffraction data obtained for the peptide
deformylase; correlating the data to generate a difference

FIG. 5 depicts a molecular model of the N-terminal resi
dues from the D1 polypeptide docked into the active site of

FIG. 6 depicts a phylogenetic analyses comparing Motif l
(SEQ ID NO: 6), Motif 2 (SEQ ID NO: 7) and Motif 3 (SEQ
ID NO: 8) of plant AtDEFl peptide deformylase With the
amino acid sequence of otherpeptide deformylase sequences.
FIG. 7 depicts a phylogenetic analyses comparing Motif l
(SEQ ID NO: 9), Motif2 (SEQ ID NO: 10) and Motif3 (SEQ
ID NO: 11) of plant AtDEF2 peptide deformylase With the
amino acid sequence of otherpeptide deformylase sequences.
FIG. 8 depicts a phylogenetic analyses comparing Motif l
(SEQ ID NO: 12), Motif 2 (SEQ ID NO: 13) and Motif 3
(SEQ ID NO: 14) of various peptide deformylase amino acid
sequences.

Like reference symbols in the various draWings indicate
50

Fourier image of the compound; and locating the region of
Arabidopsis Zhaliana peptide deformylase contacted by the

like elements.
DETAILED DESCRIPTION

compound. In some aspects, the compound is actinonin.
Provided herein are novel crystalline forms of peptide

In another embodiment, a method of modifying an inhibi

tor of Arabidopsis Zhaliana peptide deformylase activity, is
provided. The method includes obtaining a crystal including
an Arabidopsis Zhaliana peptide deformylase polypeptide
and an inhibitor; obtaining the atomic coordinates of the
crystal; correlating the atomic coordinate data With one or
more molecular modeling techniques; identifying at least one
modi?cation predicted to effect the interaction of the inhibi
tor With the polypeptide; and modifying the inhibitor based

55

60

on the prediction. In one aspect, the modi?cation is a com

inhibitor. In one aspect, the crystal comprises the amino acid
residues of SEQ ID NO: 1.

related to such crystals. Also provided are methods of using
such information to identify, design and/or modify com
pounds that modulate the activity of a peptide deformylase. In
addition, computer systems that include such information are
provided. The crystal structures and information derived
therefrom are suitable for designing and identifying, for
example, broad spectrum herbicides. Such herbicides can be
used, for example, to inhibit or prevent the groWth of unde

sirable vegetation.

puter generated modi?cation. In other aspects, the modi?ca
tion is a physical modi?cation made to the structure of the

deformylase polypeptides and atomic coordinate information

65

The crystal structure is based, at least in part, on the dis
covery of a plant nuclear gene that encodes a chloroplast

targeted peptide deformylase polypeptide. The gene has sub

US 7,445,923 B2
5

6

stantial homology to bacterial peptide deformylase. The

include aromatic to aromatic, apolar to apolar, aliphatic to
aliphatic, acidic to acidic, basic to basic, polar to polar, etc.

deduced translation of this nucleic acid sequence reveals the
presence of three conserved protein motifs associated With

Other conservative amino acid substitutions are Well knoWn

prokaryotic peptide deformylase (see e.g., FIGS. 6, 7, and 8).

20040088755, the contents of Which are incorporated herein

in the art. It Will be recognized by those of skill in the art that
generally, a total of about 20% or feWer, typically about 10%
or feWer, most usually about 5% or feWer, of the amino acids
in the Wild-type polypeptide sequence can be conservatively
substituted With other amino acids Without deleteriously

by reference.

affecting the biological activity and/or three-dimensional

Nucleic acid and amino acid sequences for plant peptide
defor'mylases are disclosed in US. Pat. No. 6,730,634, issued

May 4, 2004, and US. Patent Application Publication No.
It is to be understood that the crystalline form of a plant

structure of the molecule, provided that such substitutions do

peptide deformylase from Which the atomic structure coordi

not involve residues that are critical for activity. The folloW

nates of the invention can be obtained is not limited to Wild

ing abbreviations are used for amino acids throughout this

type Arabidopsis Zhaliana peptide deformylase polypeptide,

disclosure:

or a truncated form of the polypeptide (see e.g., SEQ ID

V:Val:Valine,
CICysICysteine,
LILeuILeucine,
YITyFTyrosine, I:Ile:Isoleucine, NIAsnIAsparagine,
P:Pro:Proline, Q:Gln:Glutamine, FIPheIPhenyIaIanine,
DIAspIAspartic
Acid,
W:Trp:Tryptophan,

NO: 1) as provided herein. Indeed, the crystals may comprise
mutants of Wild-type Arabidopsis Zhaliana peptide deformy
lase or the sequence of amino acids set forth in SEQ ID NO:1 .

Mutants can be obtained by replacing at least one amino acid

E:Glu:Glutamic

residue in the sequence of the Wild-type Arabidopsis Zhaliana

KILysILysine,

peptide deformylase or the sequence of amino acids set forth
in SEQ ID NO:1 With a different amino acid residue, or by

20

A:Ala:Alanine,

Acid,

G:Gly:Glycine,

T:Thr:Threonine,

M:Met:Methionine,

RIArgIArginine,

SISerISerine, HIHisIHistidine.
In some embodiments, it may be desirable to make muta
tions in the active site of a polypeptide, e.g., to reduce or

adding or deleting one or more amino acid residues Within the
Wild-type sequence and/or at the N- and/ or C-terminus of the

completely eliminate deformylase activity. Mutations that

Wild-type Arabidopsis Zhaliana peptide deformylase or the
ditions that are substantially similar to those used to crystal

Will reduce or completely eliminate the activity of a particular
protein Will be apparent to those of skill in the art. For
example, the amino acids identi?ed in Table 1 could be
mutated in order to reduce or eliminate the binding activity of

lize the Wild-type Arabidopsis Zhaliana peptide deformylase

Wild-type Arabidopsis Zhaliana peptide deformylase or the

sequence of amino acids set forth in SEQ ID NO:1. Prefer

25

ably, such mutants Will crystallize under crystallization con
or the sequence of amino acids set forth in SEQ ID NO:1.

The types of mutants contemplated by this invention
include conservative mutants, non-conservative mutants,
deletion mutants, truncated mutants, extended mutants,
methionine mutants, selenomethionine mutants, cysteine

30

form disul?de bridges With other Cys (C) residues or other

sulfhydryl-containing amino acids (“cysteine-like amino
acids”). The ability of Cys (C) residues and other cysteine

mutants and selenocysteine mutants. A mutant may have, but

need not have, Arabidopsis Zhaliana peptide deformylase
activity. Preferably, a mutant displays biological activity that
is substantially similar to that of the Wild-type polypeptide or
that of SEQ ID NO:1.
It Will be recognized by one of skill in the art that the types
of mutants contemplated herein are not mutually exclusive;
that is, for example, a polypeptide having a conservative

sequence of amino acids set forth in SEQ ID NO: 1.
The amino acid residue Cys (C) is unusual in that it can

35

like amino acids to exist in a polypeptide in either the reduced
free iSH or oxidized disul?de-bridged form affects Whether

Cys (C) residues contribute net hydrophobic or hydrophilic
character to a polypeptide.

While in most instances the amino acids of Wild-typeAra
bidopsis Zhaliana peptide deformylase or the sequence of
40

amino acids set forth in SEQ ID NO:1 Will be substituted With

genetically-encoded amino acids, in certain circumstances

bidopsis Zhaliana peptide deformylase or the sequence of

mutants may include genetically non-encoded amino acids.
Alternatively, in instances Where the mutant Will be prepared
in Whole or in part by chemical synthesis, virtually any non
encoded amino acids may be used, ranging from D-isomers of
the genetically encoded amino acids to non-encoded natu

amino acids set forth in SEQ ID NO:1 that are implicated in

rally-occurring natural and synthetic amino acids.

the active site of the polypeptide (e.g., amino acid residues

Conservative amino acid substitutions for many of the
commonly knoWn non-genetically encoded amino acids are

mutation in one amino acid may in addition have a truncation
of residues at the N-terminus.
In addition, conservative or non-conservative amino acid
substitutions can be made to amino acids of Wild-type Ara

45

Glyl2l, Glyl23, Leu124,Gln128,Glu169, Gly170,Cys171,
Leu172, His213, Glu2l4, His217, and Tyr178 of SEQ ID

50

Well knoWn in the art. Conservative substitutions for other

NO: 1). Such conservative or non-conservative substitutions

non-encoded amino acids can be determined based on their

can affect, e.g., the a?inity With Which wild-typeArabidopsis
Zhaliana peptide deformylase or the sequence of amino acids

physical properties as compared to the properties of the
genetically encoded amino acids.

set forth in SEQ ID NO:1 binds to a substrate. In certain
embodiments, the conservative or non-conservative amino
acid substitutions can increase the a?inity With Which Wild

55

residues to wild-typeArabidopsis Zhaliana peptide deformy

type Arabidopsis Zhaliana peptide deformylase or the
sequence of amino acids set forth in SEQ ID NO:1 binds to a
substrate.
Conservative amino acid substitutions are Well-knoWn in
the art, and include substitutions made on the basis of a

In some instances, it may be particularly advantageous or
convenient to substitute, delete from and/ or add amino acid
lase or the sequence of amino acids set forth in SEQ ID NO:1

in order to provide convenient cloning sites in cDNA encod

ing the polypeptide, to aid in puri?cation of the polypeptide,
60

etc. Such substitutions, deletions and/or additions that do not
substantially alter the three dimensional structure of the

similarity in polarity, charge, solubility, hydrophobicity and/

native Arabidopsis Zhaliana peptide deformylase or the

or the hydrophilicity of the amino acid residues involved.
Typical conservative substitutions are those in Which the

sequence of amino acids set forth in SEQ ID NO:1 Will be
apparent to those having skills in the art. These substitutions,

amino acid is substituted With a different amino acid that is a

65

deletions and/ or additions include, but are not limited to, His

member of the same class or category, as those classes are

tags, BirA tags, intein-containing self-cleaving tags, maltose

de?ned herein. Thus, typical conservative substitutions

binding protein fusions, glutathione S-transferase protein

US 7,445,923 B2
7

8

fusions, antibody fusions, green ?uorescent protein fusions,
signal peptide fusions, biotin accepting peptide fusions, and

Pharmacia) and collecting the ?oWthrough. Undigested
DEF2 remained bound to the column. Referring to FIG. 1B,
the amino acid sequence of the truncated DEF2 polypeptide is

the like.
Mutations may also be introduced into a polypeptide
sequence Where there are residues, e.g., cysteine residues,
that interfere With crystallization. Such cysteine residues can
be substituted With an appropriate amino acid that does not
readily form covalent bonds With other amino acid residues

provided.
It is understood that the term “crystalline form” includes a

polypeptide associated With a plant peptide deformylase can
include just the polypeptide, or the polypeptide complexed
With a metal, a ligand, or any other chemical entity suitable

under crystallization conditions; e. g., by substituting the cys

for crystallization With the polypeptide. An exemplary

teine With Ala, Ser or Gly. Any cysteine located in a non
helical or non-beta-stranded segment, based on secondary

polypeptide includes Arabidopsis Zhaliana peptide deformy

structure assignments, are good candidates for replacement.
It should be noted that the mutants contemplated herein
need not exhibit deformylase activity. Indeed, amino acid

fragments include optionally, the crystal may include a coor
dinated metal ion selected from the group of consisting of Fe,
Zn, Ni, or combinations thereof. Thus, “crystalline form” and
“crystal” refer to a composition comprising a polypeptide

lase, or fragments thereof, suitable for crystallization. Such

substitutions, additions or deletions that interfere With the

binding activity of Wild-type Arabidopsis Zhaliana peptide

complex in crystalline form. The term “crystal” includes

deformylase or the sequence of amino acids set forth in SEQ

native crystals, heavy-atom derivative crystals and poly-crys

ID NO:1 are speci?cally contemplated by the invention. Such
crystalline polypeptides, or the atomic structure coordinates
obtained therefrom, can be used to provide phase information

tide complex is substantially pure.

tals. “Native Crystal” refers to a crystal Wherein the polypep
20

to aid the determination of the three-dimensional X-ray struc
tures of other related or non-related crystalline polypeptides.

lution of 2.7 A. “Molecular Replacement” refers to the
method of calculating initial phases for a neW crystal of a
polypeptide Whose structure coordinates are unknown by ori

Also contemplated are homologs of the Arabidopsis

Zhaliana peptide deformylase. The present invention provides
a computer-assisted method for homology modeling an Ara

Referring to FIG. 2A, the crystal structure of DEF2 Was
determined by molecular replacement and re?ned to a reso
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enting and positioning a polypeptide Whose structure coordi

bidopsis Zhaliana peptide deformylase homolog including:

nates are knoWn Within the unit cell of the neW crystal so as to

aligning the amino acid sequence of anArabidopsis Zhaliana
peptide deformylase homolog With the amino acid sequence
of Arabidopsis Zhaliana peptide deformylase SEQ ID N011
and incorporating the sequence of the Arabidopsis Zhaliana
peptide deformylase homolog into a model of Arabidopsis
thaliana peptide deformylase derived from structure coordi

best account for the observed diffraction pattern of the neW
crystal. Phases are then calculated from the oriented and

positioned polypeptide and combined With observed ampli
30

(Jones et al., 1991, Acta Crystallogr. 47:753-70; Brunger et
al., 1998, Acta Crystallogr. D. Biol. Crystallogr. 541905-21).

nates set forth in Table 1 to yield a preliminary model of the

Arabidopsis Zhaliana peptide deformylase homolog; subject
ing the preliminary model to energy minimization to yield an
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energy minimized model; remodeling regions of the energy

orientation of the C-terminal helix (helix 3) and the confor
mation of the loop betWeen [3 strands 2 and 3, Which form part

tide deformylase homolog.
As used herein, the term “homolog” refers to the polypep

or nucleotide sequence identity, With the polypeptide, encod
ing nucleic acid molecule or any functional domain thereof,

The overall fold of the enzyme resembles the 0t+[3 confor
mation of knoWn bacterial peptide deformylases, With an
r.m.s deviation of about 1.04 A on main chain atoms relative
to the E. coli enzyme. The largest differences occur in the

minimized model Where stereochemistry restraints are vio
lated to yield a ?nal model of the Arabidopsis Zhaliana pep

tide molecule or the nucleic acid molecule Which encodes the
polypeptide, or a functional domain from said polypeptide
from a ?rst source having at least about 30%, 40% or 50%
sequence identity, or at least about 60%, 70% or 75%
sequence identity, or at least about 80% sequence identity, or
more preferably at least about 85% sequence identity, or even
more preferably at least about 90% sequence identity, and
most preferably at least about 95%, 97% or 99% amino acid

tudes to provide an approximate Fourier synthesis of the
structure of the polypeptides comprising the neW crystal
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of the ?ve-stranded central sheet. Motif I, II and III are col

ored blue, green and pink, respectively. The active site metal,
modeled as zinc due to the conditions of crystallization, is a

space-?lled sphere in the middle of the structure. Referring to
FIG. 2B, a slab vieW of the ribbon representation of trypsi
45

nolyzed AtDEF2 highlighting the active-site-metal binding
ligands (1 Cys and 2 His) from motifs II and III, respectively
(EGCLS (SEQ ID NO: 2) and QHEXXH (SEQ ID NO: 3) is
provided. As used herein, the term “active site” refers to
regions on a protein or a structural motif of a protein that are
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directly involved in the function or activity of the peptide

from a second source. The second source may be a version of

deformylase.

the molecule from the ?rst source that has been genetically
altered by any available means to change the primary amino

pocket” refer to a region of a polypeptide or a molecular

As used herein, the terms “binding site” or “binding

acid or nucleotide sequence or may be from the same or a

different species than that of the ?rst source. Homology mod
eling is further discussed beloW.
Accordingly, provided herein are crystalline forms of a
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plant peptide deformylase. Referring to FIG. 1A, limited
trypsinolysis creates a core protein that retained activity and
remained soluble in the absence of high salt concentrations.
Analysis of Wild-type and proteolyzed AtDEF2 on an 8- 1 6%
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gradient SDS-PAGE. Trypsinolysis produces a truncated
DEF2 With a mobility shift corresponding to a 3 kDa loss in
molecular mass from AtDEF2, a 24.598 kDa enzyme. The

truncated DEF2, Which loses its hexahistidyl sequence, Was

subsequently separated from undigested DEF2 by loading the
digested sample onto a HiTrap® a?inity column (Amersham
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complex comprising the polypeptide that, as a result of the
primary amino acid sequence of the polypeptide and/or its
three-dimensional shape, favorably associates With another
chemical entity or compound including ligands or inhibitors.
The crystalline form can include the tetragonal space group
symmetry P4l212 and includes a unit cell having dimensions
a, b, and c; Wherein a is about 40 A to about 60 A, b is about
40 A to about 60 A, and c is about 120 A to about 160 A; and
Wherein alpha:beta:gamma:90 degree. In some aspects, a is
about 49 A to about 52 A, b is about 49 A to about 52 A, and
c is about 143 A to about 147 A.
“Unit Cell” refers to the smallest and simplest volume

element (i.e., parallel piped-shaped block) of a crystal that is
completely representative of the unit or pattern of the crystal,

